Adverse effect · TB-500

How common is safety in humans with TB-500?

D
Grade D — no human evidenceNone systematic · effect size: not measurable · adverse
Short answerNo human evidence. As of 2 September 2026, only none systematic exist for TB-500 for safety in humans. No systemic safety data. Independent testing of vendor products finds wide variation between labelled and actual content.

What the studies show

No systemic safety data. Independent testing of vendor products finds wide variation between labelled and actual content.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in cell migration and wound repair. Full-length thymosin beta-4 has been through phase 3 trials — as an eye drop for dry eye disease, with mixed results and no approval. The injected use people buy it for, for tendon and muscle injury, has never been tested in a completed human trial. It is banned in sport and not approved anywhere.

TB-500 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is TB-500 proven to cause safety in humans?
No. There is no human evidence for it (None systematic); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
No systemic safety data. Independent testing of vendor products finds wide variation between labelled and actual content.
Is TB-500 approved for this?
No. TB-500 is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for TB-500

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →